Bessemer Group
CTKB icon

Bessemer Group’s Cytek Biosciences CTKB Stock Holding History

Bessemer Group’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3K Hold
593
– – ﹤0.01% 2312
2025
Q4 		$3K Buy
593
+281
+90% +$1.3K ﹤0.01% 2328
2025
Q3 		$1K Buy
+312
New +$1.17K ﹤0.01% 2395
2023
Q4 		– Sell
-366
Closed -$2K – 2169
2023
Q3 		$2K Buy
+366
New +$2.94K ﹤0.01% 1954

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bessemer Group's CTKB Position: Q1 2026 in Review

Bessemer Group held its Cytek Biosciences (CTKB) position steady in Q1 2026 at 593 shares worth $3K. The position accounts for ﹤0.01% of the portfolio, ranked #2312.

Bessemer Group first reported a position in CTKB in Q3 2023 and has held it in 4 quarters since. 165 funds tracked by Wall St. Rank hold CTKB as of Q1 2026.

  • Bessemer Group held 593 shares of Cytek Biosciences worth $3K as of Q1 2026.
  • Bessemer Group left its Cytek Biosciences share count unchanged in Q1 2026.
  • Cytek Biosciences made up ﹤0.01% of Bessemer Group's portfolio in Q1 2026, its #2312 holding.
  • Bessemer Group first reported a position in Cytek Biosciences in Q3 2023 and has held it in 4 quarters since.
  • 165 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2026.

Based on Bessemer Group's 13F filing for Q1 2026, filed 6 May 2026.